These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28508388)

  • 1. Positive clinical outcome in a patient with recalcitrant bullous pemphigoid treated with rituximab and intravenous immunoglobulin.
    Nguyen T; Ahmed AR
    Clin Exp Dermatol; 2017 Jul; 42(5):516-519. PubMed ID: 28508388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up.
    Ahmed AR; Shetty S; Kaveri S; Spigelman ZS
    J Am Acad Dermatol; 2016 Apr; 74(4):700-8.e3. PubMed ID: 26851830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
    Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
    Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infantile Bullous Pemphigoid Treated Using Intravenous Immunoglobulin: Case Report and Review of the Literature.
    Tekin B; Yücelten AD
    Pediatr Dermatol; 2015; 32(5):723-6. PubMed ID: 26119800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Half-half" blisters in bullous pemphigoid successfully treated with adjuvant high-dose intravenous immunoglobulin.
    Pacheco D; Lopes L; Soares-Almeida L; Marques MS; Filipe P
    Acta Dermatovenerol Alp Pannonica Adriat; 2012 Sep; 21(3):59-61. PubMed ID: 23267874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.
    Lamberts A; Euverman HI; Terra JB; Jonkman MF; Horváth B
    Front Immunol; 2018; 9():248. PubMed ID: 29520266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies.
    Czernik A; Bystryn JC
    Arch Dermatol; 2008 May; 144(5):658-61. PubMed ID: 18490594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory bullous pemphigoid with fatal outcome in a young patient.
    Cruz MJ; Santos P; Morais P; Barreto F; Azevedo F
    Int J Dermatol; 2013 May; 52(5):601-2. PubMed ID: 23590375
    [No Abstract]   [Full Text] [Related]  

  • 9. Refractory antilaminin γ1 pemphigoid successfully treated with intravenous immunoglobulin and mycophenolate mofetil.
    Alloo A; Strazzula L; Rothschild B; Hawryluk E; Levine D; Hoang MP; Koga H; Hashimoto T; Kroshinsky D
    J Eur Acad Dermatol Venereol; 2014 Oct; 28(10):1401-3. PubMed ID: 24397852
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment.
    Ahmed AR
    J Am Acad Dermatol; 2001 Dec; 45(6):825-35. PubMed ID: 11712025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bullous Pemphigoid Successfully Treated with Rituximab].
    Silva N; Costa A; Salvador F; Serradeiro E
    Acta Med Port; 2017 Mar; 30(3):243-246. PubMed ID: 28550834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of rituximab in a case of refractory bullous pemphigoid].
    Reguiaï Z; Tchen T; Perceau G; Bernard P
    Ann Dermatol Venereol; 2009 May; 136(5):431-4. PubMed ID: 19442800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Where does rituximab fit in the treatment of autoimmune mucocutaneous blistering skin disease?
    Nigam R; Levitt J
    J Drugs Dermatol; 2012 May; 11(5):622-5. PubMed ID: 22527431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.
    Kasperkiewicz M; Shimanovich I; Ludwig RJ; Rose C; Zillikens D; Schmidt E
    J Am Acad Dermatol; 2011 Sep; 65(3):552-558. PubMed ID: 21641080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe bullous pemphigoid in an infant--successful treatment with rituximab.
    Schulze J; Bader P; Henke U; Rose MA; Zielen S
    Pediatr Dermatol; 2008; 25(4):462-5. PubMed ID: 18789089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission Time after Rituximab Treatment for Autoimmune Bullous Disease: A Proposed Update Definition.
    Iranzo P; Pigem R; Giavedoni P; Alsina-Gibert M
    Skin Pharmacol Physiol; 2015; 28(5):255-6. PubMed ID: 26021780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report.
    Foster CS; Chang PY; Ahmed AR
    Ophthalmology; 2010 May; 117(5):861-9. PubMed ID: 20045562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infantile bullous pemphigoid successfully treated with combined pulse corticosteroids and high-dose IVIG.
    Wawrzycki B; Krasowska D; Pietrzak A; Szumilo J; Blazowski L; Pietraszek-Mamcarz J; Lotti T
    Dermatol Ther; 2018 Sep; 31(5):e12635. PubMed ID: 30216603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Use of Rituximab and Intravenous Immunoglobulin for Severe Autoimmune Cicatricial Conjunctivitis-An Interventional Case Series.
    Steger B; Madhusudan S; Kaye SB; Stylianides A; Romano V; Maqsood SE; Harper J; Ahmad S
    Cornea; 2016 Dec; 35(12):1611-1614. PubMed ID: 27661067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bullous pemphigoid treated with intravenous immunoglobulin.
    Tuchinda P; Ritchie S; Gaspari AA
    Cutis; 2014 May; 93(5):264-8. PubMed ID: 24897141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.